Irinotecan liposome injection regimen 'a new reference' for metastatic pancreatic cancer

Irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin prolonged OS compared with nab-paclitaxel and gemcitabine as initial treatment for patients with metastatic pancreatic ductal adenocarcinoma, study results showed.The irinotecan liposome injection regimen, known as NALIRIFOX, also exhibited a manageable safety profile consistent with that of each treatment component,

Related Keywords

California ,United States ,San Francisco ,Mindy Valcarcel ,Los Angeles ,Zeva Wainberg ,Daiichi Sankyo Astrazeneca ,Astrazeneca Medimmune ,Bydevin Mclaughlin ,University Of California ,Amgen ,Jonsson Comprehensive Cancer Center ,Novartis ,Eli Lilly Co ,Pfizer ,Merck Kga ,Ipsen Pharmaceuticals ,Merck Kgaa ,Bristol Myers Squibb ,Cancers Symposium ,Arcus Biosciences ,Eli Lilly ,Five Prime Therapeutics ,Comprehensive Cancer Center ,